TOP TEN perturbations for NM_000041 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000041
Selected probe(set): 203381_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000041 (203381_s_at) across 5392 perturbations tested by GENEVESTIGATOR:

conditioned medium study 1 (HS27a) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):5.725791
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS27a)
CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.

SDF study 4 / untreated MDA Mb231 cell sample

Relative Expression (log2-ratio):5.2677746
Number of Samples:3 / 6
Experimental SDF study 4
MDA Mb231 cells treated with 75nM stromal derived factor (SDF; Cxcl12) for 6h.
Control untreated MDA Mb231 cell sample
Untreated MDA Mb231 cells harvested after 6h.

HCC study 20 (CDX; Hep-G2; ectopic) / HCC study 20 (PDX; ectopic)

Relative Expression (log2-ratio):-5.0298357
Number of Samples:3 / 11
Experimental HCC study 20 (CDX; Hep-G2; ectopic)
Tumor tissue biopsy samples from Hep-G2 cell line-derived xenograft (CDX) ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks.
Control HCC study 20 (PDX; ectopic)
Tumor tissue biopsy samples from patient-derived xenograft (PDX) sample ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. Donor tumor tissue was obtained intraoperatively during liver resection from three patients. All three patients had hepatocellular carcinoma confirmed by histology. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks.

stem cell differentiation study 47 (BMP-2; IBMX; 7d) / stem cell differentiation study 47 (0d)

Relative Expression (log2-ratio):4.7644157
Number of Samples:3 / 6
Experimental stem cell differentiation study 47 (BMP-2; IBMX; 7d)
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 ?M). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 ?C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 ?g/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 ?g/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 250 ?M IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).
Control stem cell differentiation study 47 (0d)
Undifferentiated bone marrow-derived mesenchymal stem cell line (MSC) without any treatment. Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 ?C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 ?g/ml streptomycin) and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).

stem cell differentiation study 47 (BMP-2; IBMX; 7d) / stem cell differentiation study 47 (BMP-2; IBMX; 1d)

Relative Expression (log2-ratio):4.728075
Number of Samples:3 / 3
Experimental stem cell differentiation study 47 (BMP-2; IBMX; 7d)
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 ?M). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 ?C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 ?g/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 ?g/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 250 ?M IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).
Control stem cell differentiation study 47 (BMP-2; IBMX; 1d)
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 24 hours in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 ?M). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 ?C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 ?g/ml streptomycin). Subsequently PMCs were differentiated for 1 day in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 ?g/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 250 ?M IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).

stem cell differentiation study 47 (BMP-2; IBMX; 7d) / stem cell differentiation study 47 (BMP-2; TGFb; 7d)

Relative Expression (log2-ratio):4.584914
Number of Samples:3 / 3
Experimental stem cell differentiation study 47 (BMP-2; IBMX; 7d)
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 ?M). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 ?C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 ?g/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 ?g/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 250 ?M IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).
Control stem cell differentiation study 47 (BMP-2; TGFb; 7d)
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and transforming growth factor beta (TGFb, 5 ng/ml). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 ?C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 ?g/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 ?g/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 5 ng/ml TGFb), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).

monocyte activation study 1 (NOD2L/TLR/1L; 24h) / untreated monocyte sample (24h)

Relative Expression (log2-ratio):-4.5142403
Number of Samples:5 / 5
Experimental monocyte activation study 1 (NOD2L/TLR/1L; 24h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D?sufficient (100 nM) human serum and activated for 24 hours with 1 ug/ml muramyl dipeptide (nucleotide-binding oligomerization domain-containing protein 2 ligand, NOD2L) and 1 ug/ml mycobacterial 19-kDa triacylated lipopeptide (TLR2/1 ligand, TLR2/1L). This type of activation is via nucleotide-binding oligomerization domain-containing protein 2 (NOD2) and heterodimeric Toll-like receptor 2 and Toll-like receptor 1 (TLR2/1).
Control untreated monocyte sample (24h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D?sufficient (100 nM) human serum and collected after 24 hours for RNA isolation.

IL-4; GM-CSF study 1 (late) / untreated monocyte sample

Relative Expression (log2-ratio):4.4356623
Number of Samples:6 / 12
Experimental IL-4; GM-CSF study 1 (late)
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 5 days. Cytokine treatment was repeated at day 3.
Control untreated monocyte sample
Freshly isolated human monocytes from healthy donors.

TGF-?3 study 1 (late) / untreated mesenchymal stem cell sample

Relative Expression (log2-ratio):4.2533884
Number of Samples:3 / 5
Experimental TGF-?3 study 1 (late)
Cultured mesenchymal stem cells from human bone marrow aspirates of healthy donors. Cells were stimulated with 10ng/ml of recombinant TGF-?3 for 21 days. (Warning: Experiment with gender bias).
Control untreated mesenchymal stem cell sample
Cultured mesenchymal stem cells from human bone marrow aspirates of healthy donors. Cells were not treated. (Warning: Experiment with gender bias).

BMP-2 study 2 (late) / untreated mesenchymal stem cell sample

Relative Expression (log2-ratio):4.2340794
Number of Samples:3 / 5
Experimental BMP-2 study 2 (late)
Cultured mesenchymal stem cells from human bone marrow aspirates of healthy donors. Cells were stimulated with 100ng/ml of recombinant BMP-2 for 21 days. (Warning: Experiment with gender bias).
Control untreated mesenchymal stem cell sample
Cultured mesenchymal stem cells from human bone marrow aspirates of healthy donors. Cells were not treated. (Warning: Experiment with gender bias).